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Abstract
Background: We retrospectively reviewed the clinical features and surgical outcomes of patients with a surgically
resected NSCLC invading chest wall in order to identify prognostic factors that impact long term survival.
Methods: Between January 1990 and December 2009, 107 patients who underwent surgical resection for chest
wall invading NSCLC were reviewed. Tumors invading only the parietal pleura were defined as superficial invasions,
and those involving the soft tissue or ribs were defined as deep invasions.
Results: There were 91 men and 16 women; median age was 64 years (range 30 to 80 years). Overall 5 year
survival rate was 26.3%. The univariate prognostic factors for survival included gender, extent of resection
(pneumonectomy vs lobectomy), tumor size(> 5 cm vs ≤ 5 cm), nodal status (N0 or N1 vs N2), completeness
of resection (complete vs incomplete) and completeness of adjuvant chemotherapy. At multivariate analysis,
five independent prognostic factors were shown; depth of invasion (superficial vs deep), tumor size, nodal
status, completeness of resection, and completeness of adjuvant chemotherapy. In patients with completely
resected T3N0 NSCLC, completion of chemotherapy is the only prognostic factor for long term survival.
Conclusions: Completeness of resection, nodal status, depth of invasion, tumor size, and adjuvant chemotherapy
were prognostic factors for long-term survival in NSCLC patients with chest wall invasion. Because of poor
prognosis in cases with chest wall invasion that have N2 positive LN, that is difficult to achieve complete resection
and that need pneumonectomy, definite chemoradiotherapy or neoadjuvant chemoradiotherapy should be
considered first in these cases.
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Background
Although incomplete resection and the presence of
nodal involvement, especially in the N2 station, have
been consistently reported as poor prognostic factors of
non-small cell lung cancer with chest wall invasion,
other factors influencing survival are still unclear [1-11].
Whether adjuvant chemotherapy or radiotherapy is
mandatory for patients with completely resected chest
wall invading NSCLC without nodal involvement
remains under debate [2,5,6,12,13].
Also, there are suggestions that the depth of chest wall
invasion may influence prognosis following resection of
lung cancer [11].
Herein, we retrospectively reviewed the clinical fea-
tures and surgical outcomes of patients with a surgically
resected NSCLC invading chest wall in order to identify
prognostic factors that impact long term survival and to
suggest the optimal treatment strategy according to
these prognostic factors.
Materials and methods
Patients
Between January 1990 and December 2009, 107 patients
with chest wall invading NSCLC were surgically treated
at our institution. Patient records were obtained from a
database that contained prospectively collected data
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malignancies at our departments. Among 2,138 patients
in our data cohort, 282 patients with pT3 NSCLC were
selected. Patients with a T3 tumor in the invasion of
mediastinal pleura, diaphragm, or the pericardium were
excluded. Also, patients with tumor close to main
bronchus (< 2 cm) were not included. Patients who
received any type of preoperative chemotherapy or
radiotherapy, or who underwent wedge resection or seg-
mentectomy, were not selected. However, the subset of
patients with T3 superior sulcus tumor included in this
study had a chest wall invasion confined only to the par-
ietal pleura or the soft tissue in thorax, which was com-
pletely removed through a single incision.
The charts and pathologic report of 107 patients were
reviewed. Demographic data and first presenting symp-
toms were collected. The preoperative evaluation included
a physical examination, routine blood tests, electrocardio-
graphy, pulmonary function test, and a lung perfusion
scan if necessary. The routine staging workup included a
chest computed tomography (CT) scan, abdomen CT scan
or ultrasonography and fiberoptic bronchoscopy. Bone
scintigraphy was routinely performed before 2007 in 104
patients. Fluorodeoxyglucose positron emission tomogra-
phy (FDG-PET) was performed in 14 patients since 2003.
Mediastinoscopy was selectively performed in 28 patients
when it was suspected that the patient had enlarged med-
iastinal lymph nodes on the CT scan or PET scan. Cancers
were staged according to the the 6
th edition of TNM Clas-
sification of Malignant Tumors.
Surgical technique and pathologic examination
In all patients including those with a superior sulcus
tumor except for one patient, posterolateral thoracotomy
was performed. Systematic lymph node dissection was
completed in all patients.
When chest wall invasion was preoperatively suspected,
a chest wall resection including the affected rib was sched-
uled. Extrapleural resection was performed when the par-
ietal pleura could be easily freed from the chest wall. In
case of intraoperative evidence of deep parietal invasion, a
decision on whether a chest wall resection or a wide extra-
pleural resection with involved soft tissue should be per-
formed was determined according to each surgeon’s
decision. In these cases, resection margin was confirmed
intraoperatively through the frozen section for complete
resection. Pneumonectomy was performed whenever the
mass crossed over the major fissure.
In a pathological examination of the resected speci-
mens, tumors invading only the parietal pleura were
defined as superficial invasions, and those involving the
soft tissue or ribs were defined as deep invasions.
A complete (R0) resection was defined as a pathologic
demonstration of negative tissue margins. Patients who
had a complete gross resection in the thoracotomy but
were found to have positive margins or extracapsular
invasion of retrieved LN on the final pathologic review
were classified as having undergone microscopically
incomplete (R1) resections. A gross residual disease after
attempted resection was classified as R2.
Adjuvant treatment
There was no consistent institutional protocol with regard
to adjuvant treatment for patient with surgically resected
NSCLC invading the chest wall. Adjuvant treatment was
determined by each surgeon and the referred oncologist.
Three or more cycles of platinum based chemotherapy
were regarded as a completion of chemotherapy. When
radiotherapy was performed, it consisted of parietal radio-
therapy in cases of stage IIB diseases, and parietal and
mediastinal radiotherapy in cases of stage IIIA diseases.
Recurrences and survival
A recurrence of the ipsilateral chest wall, lung, pleura,
mediastinum, or cervical lymph node was defined as loco-
regional recurrences. The remaining recurrences were
defined as systemic recurrences.
Survival was calculated from the date of surgery until
death or the date of the last follow-up. Survival rates,
including postoperative and non-cancer related deaths,
were calculated by the Kaplan-Meier method and com-
pared using the log-rank test. Percentage comparisons
were made by the c
2 test. Univariate and multivariate ana-
lysis were performed using the Cox proportional hazards
regression model to determine factors potentially predict-
ing survival. Factors identified at p < 0.20 by univariate
analysis and known prognostic factors such as age and
radiotherapy were selected for inclusion in a multivariate
Cox proportional hazards regression model. All statistical
analyses were performed using the SPSS 12.0 software
package (SPSS, Chicago, Illinois). Results were considered
significant if the p value was less than 0.05.
Results
Demographics
There were 91 men and 16 women; the median age was
64 years (range 30 to 80 years). One or more of the fol-
lowing symptoms were present in the 96 patients: chest
pain (n = 45, 41%), cough (n = 47, 44%), hemoptysis or
blood tinged sputum (n = 19, 18%), and dyspnea (n = 7,
7%). Eleven patients (10%) were asymptomatic. Seventy
one (66%) patients had a history of smoking. The mean
FEV1 was 77% of the predicted value (range 22 to 133%).
A superior sulcus tumor occurred in 17 (16%) patients.
Surgical outcomes and pathologic examinations
Fifty five (54%) lobectomies, 4 (4%) bilobectomies and 45
(42%) pneumonectomies were performed. A chest wall
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(27%) and 78 (73%) patients, respectively. After the chest
wall resection, large chest wall defects were repaired
using a prosthesis in 14 patients. The operative mortality
was 5% (n = 5). Respiratory failure was the only cause of
death. Perioperative complications occurred in 22 (21%)
patients. There were 12 pulmonary complications such as
pneumonia or atelectasis. Among them, 6 patients suf-
fered from acute respiratory distress syndrome (ARDS)
which needed mechanical ventilator care. Bronchopleural
fistula (BPF) and bleeding necessitating re-exploration
occurred in one patient, respectively.
The mean tumor diameter was 6.2 cm (range, 2 to
15 cm). There were 60 (56%) squamous cell carcinomas
and 25 (23%) adenocarcinomas. In 67 (63%) patients,
tumoral invasion was limited to parietal pleura; in 40
(37%) patients, it extended to the soft tissue or ribs. Patho-
logic stages were T3N0 in 64(60%) cases, T3N1 in 19
(18%) cases and T3N2 in 24 (22%) cases. Complete resec-
tion was achieved in 90 (84%) cases. Among R1 resection,
there were 11 cases in the positive lateral resection margin
and 5 cases in extracapsular invasion of retrieved lymph
nodes. R2 resection occurred in 1 patient. Lymphovascular
invasion was found in 18 patients. These results are sum-
marized in Table 1.
Adjuvant treatments
Among the 102 patients who did not die perioperatively,
fifty one patients were referred for adjuvant chemotherapy.
However, only 35 (69%) patients completed adjuvant che-
motherapy. In particular 19 patients (29.7%) out of 64
patients with pT3N0 received adjuvant chemotherapy.
Eight patients refused chemotherapy after one or two
cycles of chemotherapy. During the 1
st or 2
nd chemother-
apy, systemic metastasis was found in 5 patients. Treat-
ment-related toxicity, such as pneumonia or BPF,
occurred in 3 patients, causing a halting of any further
treatment. Chemotherapy related mortality occurred in
one patient due to pneumonia and septic shock. Post-
operative radiotherapy was carried out in 51 (50%)
patients. Eighteen patients received postoperative chemor-
adiotherapy. No adjuvant treatment could be considered
in 18 patients due to poor performance status and patient
refusal.
Recurrences and survivals
Median follow up time was 16 months. Recurrences
occurred in 54 patients. Eleven patients had only loco-
regional recurrences and 8 patients had loco-regional
recurrences and systemic recurrences simultaneously.
T h el o c a t i o n so ft h es y s t e m i cr e c u r r e n c e sw e r ea sf o l -
l o w s :L u n g( n=1 5 ) ,b r a i n( n=1 5 ) ,b o n e( n=1 1 ) ,l i v e r
(n = 5), adrenal gland (n = 3) and others (n = 4). Twenty
nine patients are currently alive. Out of 78 patients who
were not alive during the follow-up period, 46 patients
(59%) died within 1 year after the operation. The causes
of 1 year mortality were as follows: cancer-related (n =
25, 54%), pneumonia or respiratory failure (n = 16, 35%),
others (n = 3, 7%) and unknown (n = 2, 4%). One year
mortality was higher in patients who underwent pneu-
monectomy compared to those who underwent lobect-
omy (57% vs 31%, p = 0.011). The median survival was
15.9 months and overall 5 year survival rate was 26.3%.
According to the N status, 5 year survival was 37.4%,
21.1% and 4.6% in cases of N0, N1, and N2 disease,
respectively (p = 0.047, Figure 1). The 5 year survival rate
of patients with complete resection (31.7%) was statisti-
cally higher than those with incomplete resection (7.5%,
p < 0.001, Figure 2). The univariate prognostic factors for
survival included gender (p = 0.029), extent of resection
(pneumonectomy vs lobectomy, p = 0.041), tumor size(>
5c mv s≤ 5c m ,p = 0.001), nodal status (N0 or N1 vs
N2, p = 0.029), completeness of resection (complete vs
incomplete, p < 0.001) and completeness of adjuvant che-
motherapy (p < 0.001). At multivariate analysis, five inde-
pendent prognostic factors were shown; depth of
invasion (superficial vs deep, p = 0.035), tumor size (p =
0.007), nodal status (p = 0.001), completeness of resec-
tion (p < 0.001), and completeness of adjuvant che-
motherapy (p < 0.001, Table 2).
Table 1 Demographic, surgical outcomes and pathologic
features
N = 107
Age (years, median (range)) 64.0 (30-80)
Sex (male) 91 (85%)
FEV1 (liter, mean ± SD) 2.0 ± 0.8
FEV1 (%, mean ± SD) 76.5 ± 25.9
Superior sulcus tumor 17 (16%)
Extent of resection
Lobectomy 58 (54%)
Bilobectomy 4 (4%)
Pneumonectomy 45 (42%)
Type of resection
Chest wall resection 29 (27%)
Extrapleural resection 78 (73%)
Mortality 5 (5%)
Tumor size (mean ± SD) 6.2 ± 2.5
Depth of chest wall invasion
Superficial invasion 67 (63%)
Deep invasion 40 (37%)
Nodal status
N0 64 (60%)
N1 19 (18%)
N2 24 (22%)
Lymphovascular invasion 18 (17%)
FEV1; forced expiratory volume in 1 second
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tion of adjuvant chemotherapy were statistically higher
than those of patients without completion of adjuvant
chemotherapy (5 year survival rate 46.7% vs 16.6%). Sta-
tistical analysis for cancer-specific survival showed that
the survival benefit was higher in the patient groups
who received chemotherapy (5 year survival rate 45.8%
vs 21.8%, p = 0.001). And in patients with completely
resected T3N0 NSCLC, the completion of chemotherapy
is the only prognostic factor for long term survival (5
year survival rate 68.8% vs 29.7% p = 0.011, Figure 3) in
univariate analysis. Our study also revealed that there
was no statistical difference in survival with or without
adjuvant radiotherapy (5 year survival rate 23.8% vs
29.9%, p = 0.618).
Discussion
T h i ss t u d yd e m o n s t r a t e dt h a tt h el o n g - t e r ms u r v i v a lo f
patients with chest wall invading NSCLC were indepen-
dently related to not only nodal status and R0 resection
which have been consistently reported as prognostic fac-
tors, but also the depth of invasion, tumor size and
adjuvant chemotherapy.
Since technical feasibility and the long-term survival of
the surgically resected NSCLC invading chest wall were
reported in 1947 [14], surgical resection has been the
key component in the management of most patients
with chest wall invading NSCLC. Except for the incom-
pleteness of resection and the presence of lymph node
metastasis, other factors influencing on survival are still
unclear. In particular, controversies remain as to how
extensive a resection should be [7-9,15,16] and on the
role chemotherapy or radiotherapy [5,6,12,13].
Mean FEV1 of the patients enrolled in this study
(76.5%) was significantly lower than that of the patients
in the total cohort (92.1%) and this is thought to be the
reason for high incidence of death due to pneumonia
during the follow up period.
We performed a pneumonectomy in cases of large
tumor that invaded to fissure and adjacent lobe. Rela-
tively high percentage of pneumonectomy (42%) was per-
formed compared to previous studies that reported
percentage of 20-27% [7,8,10]. In the patients with tuber-
culosis and other inflammatory lung disease which were
frequent in Korea, pneumonectomy was performed in
cases large tumor crossed over major fissure and remnant
lung volume is not enough. That’s the reason why the
incidence of pneumonectomy was high. Larger tumor
size and high incidence of respiratory related mortality
seemed to be attributable to significantly higher 1-year
mortality of the patients who received pneumonectomy.
Hence, pneumonectomy should be avoided in patients
with chest wall invasion.
As previously reported [7-9], R0 resection and the
absence of N2 disease was revealed as better prognostic
factors for long term survival of patients with chest wall
invading NSCLC in this study.
The prognostic significance of the degree of the chest
wall invasion was not reflected in the 7
th TNM classifi-
cation but the sub-classification of the T3 stage and
prospective data collection were recommended for
future revision [17]. There are several studies [1,7,8]
including ours, that report the better prognosis of a
patient with tumor invasion in the parietal pleura com-
pared to deep invasion. In case of superficial invasion,
extrapleural resection is thought to be an adequate
treatment option, considering the fact that there were
Figure 1 Survival curve according to node involvement (thick
solid line: N0, solid line: N1, dotted line: N2).
Figure 2 Survival curve according to completion resection
(solid line: complete resection, dotted line: non complete
resection).
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the patients with parietal pleural invasion (N = 67), who
received extra-pleural resection (N = 57) and chest wall
resection (N = 10) (29.7% vs 23.3%, p = 0.832), and the
high incidence of complications among the patients who
received chest wall resection [8,11]. In cases of deep
invasion, moreover, there are no statistical differences
between group of extrapleural resection and group of
chest wall resection in terms of locoregional recurrence
rates and 5 year overall survival rates if R0 resection
was achieved.
Unlike the 6
th edition of the TNM staging, the T sta-
ging was sub-classified as 3 cm, 5 cm and 7 cm according
to the tumor size in the 7
th edition of the TNM staging
[17], and what it implicates is that the tumor size is an
independent prognostic factor of NSCLC. The results of
our study also show that the tumor size independently
influences the prognosis of the NSCLC patient with chest
wall invasion similar to the in other study [10].
The role of adjuvant chemotherapy in patients with
completely resected NSCLC has been evaluated in many
randomized clinical trials and meta-analysis. Cancer Care
Ontario and American Society of Clinical Oncology con-
cluded that adjuvant cisplatin-based chemotherapy is
recommended for routine use in patients with stages IIA,
IIB according to the 6
th edition of TNM Classification of
Malignant Tumors [12]. However, De Pas et al [13] have
asserted that the efficacy of adjuvant chemotherapy
should be assessed separately in the T1-2N1 and T3N0
subgroups considering the fact that the efficacy of adju-
vant chemotherapy usually varies according to lymph
node status [14] and differences in biological behavior
between subgroups. And they recommended that a
pooled-analysis of the existing data would quickly and
with limited effort provide a preliminary answer. Our
result demonstrated that systemic recurrence occurred in
about 80% of patients whom recurrences had occurred
in, and adjuvant chemotherapy was also effective in
terms of long-term survival especially in completely
resected T3N0 patients. The cancer- specific survival was
calculated because there was a subset of patients who
could not receive chemotherapy due to their poor perfor-
mance status and died of reasons such as pneumonia.
Statistical analysis showed that the survival benefit was
higher in the patient groups who received chemotherapy.
These results implicate the possible benefit for
Table 2 Univariate and multivariate analysis for long term survivals
Univariate analysis Multivariate analysis
p value Odds ratio 95% CI p value Odds ratio 95% CI
lower upper lower upper
Sex (male/female) 0.029 2.10 1.01 4.37 0.270 1.59 0.70 3.61
Age(≤ 65/> 65)) 0.278 0.78 0.50 1.22 NA NA NA NA
Extent of resection (pneumonectomy/lobectomy) 0.041 1.59 1.02 2.49 0.410 1.24 0.75 2.06
Type of resection (Extrapleural resection vs chest wall resection) 0.145 0.70 0.43 1.13 0.257 1.42 0.77 2.62
Tumor size(≤ 5 cm/> 5 cm) 0.001 0.44 0.27 0.71 0.007 0.46 0.27 0.81
Lymphovascular invasion (no/yes) 0.151 0.66 0.38 1.16 0.126 0.62 0.34 1.14
N2 lymph node involvement (N0,1/N2) 0.029 0.57 0.35 0.94 0.000 0.34 0.19 0.61
R0resection (R0/R1,2) 0.000 0.32 0.18 0.56 0.000 0.26 0.13 0.49
Depth of invasion (superficial/deep) 0.148 0.72 0.46 1.12 0.035 0.56 0.33 0.96
Superior sulcus tumor (no/yes) 0.939 1.02 0.58 1.83 NA NA NA NA
Completion of chemotherapy (no/yes) 0.000 3.18 1.86 5.41 0.000 4.83 2.47 9.43
Radiotherapy (no/yes) 0.618 0.89 0.57 1.40 NA NA NA NA
NA; not available
Figure 3 Survival curve according to completion of
chemotherapy in patients with completely resected T3N0
NSCLC (solid line: completion group, dotted line: non
completion group).
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chest wall invasion although all confounding comorbid-
ities were not completely reflected in cancer-specific sur-
vival. However, the fact that only 35 patients out of 107
patients, enrolled in this study, completed chemotherapy
suggests the likelihood of preoperative chemotherapy in
terms of expansion of delivery rate in definite preopera-
tive chest wall invading T3 patients and the necessity of
research in this area.
The role of adjuvant radiotherapy in patients with chest
wall invading NSCLC is still controversial. Although two
reports [15,18] about beneficial effect of adjuvant radio-
therapy have been published, other series [2,5,7,19] have
not showed any improvement in survival with use of post-
operative radiotherapy. Our study also revealed that there
was no statistical difference in survival with or without
adjuvant radiotherapy.
The proposed strategy based upon prognostic factors
mentioned above are as follow: Mediastinoscopy should
be done irrespective of the chest CT or PET-CT results
and neoadjuvant chemotherapy should be initiated if N2 is
confirmed. Neoadjuvant chemoradiotherapy should be
considered if the resection margins are expected to be
insufficient due to large tumor size or deep invasion in the
posterior location like Pancoast tumor [20,21]. Pneumo-
nectomy should be avoided whenever possible because not
only cancer related death but also respiratory related
death is significantly high in this group of patients. If the
tumor invades only the parietal pleura and separates with-
out any remaining tumor tissue, an extrapleural resection
could be done. Otherwise, chest wall resection should be
performed to secure the wide resection margin. Postopera-
tive adjuvant chemotherapy could be considered in
patients with completely resected T3N0 chest wall invad-
ing tumors.
Limitations
A small number of patients and the retrospective method
of reviewing the data remain as limitations of the study.
The same protocol was not applied because the data were
collected from a long period of time. However, mediastinal
lymph node dissection was performed and a platinum
based chemotherapy agent was used in all patients and
hence, treatment strategy was relatively consistent.
Patients with a superior sulcus tumor were included in
this study, unlike many other studies, that exclude them
due to different behaviors of the disease itself. However,
patients with a superior sulcus tumor invading the struc-
ture beyond the thorax were excluded in this study and
the influence of the included patients with superior sul-
cus tumor might be small because the survival differences
between patients with superior sulcus tumor and those
with non superior sulcus tumor were insignificant.
Long term survival benefit of adjuvant chemotherapy
after lung cancer surgery is known to be approximately
5%, whereas the 5 year survival benefit in this study
exceeded 30%. This result seems to be the influence of
patients whose postoperative performance was poor,
included in the group of patients who did not receive
chemotherapy. Hence, we calculated the cancer-specific
survival rate but we think that this was not enough to
completely exclude the effect of selection bias as well.
Accordingly, this study has a hypothesis generating
effect regarding the role of chemotherapy in lung cancer
patients with chest wall invasion.
Conclusion
Completeness of resection, nodal status, depth of inva-
sion, tumor size, and adjuvant chemotherapy were prog-
nostic factors for long-term survival in NSCLC patients
with chest wall invasion. Because of poor prognosis in
cases with chest wall invasion that have N2 positive LN,
that is difficult to achieve complete resection and that
need pneumonectomy, definite chemoradiotherapy or
neoadjuvant chemoradiotherapy should be considered
first in these cases. Further verification is needed
through a larger group study due to the small sample
size and retrospectively reviewed data.
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